Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Marguerite Le Marois"'
Autor:
Marguerite, Le Marois, Camille, Sanson, Magali-Anne, Maizières, Michel, Partiseti, G Andrees, Bohme
Publikováno v:
Naunyn-Schmiedeberg's Archives of Pharmacology. 396:161-166
Clozapine is an atypical neuroleptic used to manage treatment-resistant schizophrenia which is known to inhibit cardiac hERG/K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4536ccfd145f74b1b9f35d6c4e6cf374
https://doi.org/10.1007/s00210-022-02314-3
https://doi.org/10.1007/s00210-022-02314-3
Publikováno v:
Expert Opinion on Investigational Drugs
Expert Opinion on Investigational Drugs, Taylor & Francis, 2021, ⟨10.1080/13543784.2021.1928073⟩
Expert Opinion on Investigational Drugs, 2021, ⟨10.1080/13543784.2021.1928073⟩
Expert Opinion on Investigational Drugs, Taylor & Francis, 2021, ⟨10.1080/13543784.2021.1928073⟩
Expert Opinion on Investigational Drugs, 2021, ⟨10.1080/13543784.2021.1928073⟩
International audience; Introduction: Mood disorders are severe yet frequent psychiatric disorders worldwide, comprising major depressive disorder (MDD) and bipolar disorders (BD). Their treatment remains poorly effective. Recently, growing evidence
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a88d8f713d5c11a2768e93532c99a815
https://hal.archives-ouvertes.fr/hal-03361479
https://hal.archives-ouvertes.fr/hal-03361479
Autor:
Raoul Belzeaux, Olivier Blin, Thomas Soeiro, Catherine Cassé-Perrot, Clémence Lacroix, Claas Röhl, Romain Guilhaumou, Marguerite Le Marois, Elisabeth Jouve, Joëlle Micallef
Publikováno v:
Thérapie
Thérapie, 2021, 76 (2), pp.111-119. ⟨10.1016/j.therap.2020.12.007⟩
Thérapie, 2021, 76 (2), pp.111-119. ⟨10.1016/j.therap.2020.12.007⟩
International audience; Clinical trials involving brain disorders are notoriously difficult to set up and run. Innovative ways to develop effective prevention and treatment strategies for central nervous system (CNS) diseases are urgently needed. New
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab4c58d5925ace1923917170a44ca09c
https://pubmed.ncbi.nlm.nih.gov/33358366
https://pubmed.ncbi.nlm.nih.gov/33358366
Publikováno v:
Australian and New Zealand Journal of Psychiatry
Australian and New Zealand Journal of Psychiatry, 2022, 56 (1), pp.96-96. ⟨10.1177/00048674211010340⟩
Australian and New Zealand Journal of Psychiatry, 2022, 56 (1), pp.96-96. ⟨10.1177/00048674211010340⟩
International audience
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fd88425b9a9f700322068fd311e56dd
https://doi.org/10.1177/00048674211010340
https://doi.org/10.1177/00048674211010340
Autor:
Camille Sanson, Veronique Ballet, Thierry Carriot, Magali-Anne Maizières, Marguerite Le Marois, Michel Partiseti, Céline Chantoiseau, Georg Andrees Bohme
Publikováno v:
European Journal of Pharmacology. 886:173542
Cannabidiol (CBD) is a non-psychoactive component of Cannabis which has recently received regulatory consideration for the treatment of intractable forms of epilepsy such as the Dravet and the Lennox-Gastaut syndromes. The mechanisms of the antiepile
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::079e0af0270cb3a1bc9b488892db527f
https://doi.org/10.1016/j.ejphar.2020.173542
https://doi.org/10.1016/j.ejphar.2020.173542